Our observation that 1E5 has a more potent effect in KRAS mutant cells than KRAS wild-type cells further supports the current efforts in targeting mutant KRAS-induced pathways in pancreatic cancer [20]. Here, KRAS is linked to familial pancreatic carcinoma.